mesalamine

Summary

Summary: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)

Top Publications

  1. ncbi Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
    Michael A Kamm
    Department of Gastroenterology, St Mark s Hospital, Watford Road, Harrow, United Kingdom
    Gastroenterology 132:66-75; quiz 432-3. 2007
  2. pmc PPARgamma as a new therapeutic target in inflammatory bowel diseases
    L Dubuquoy
    INSERM U795 ex E114, Clinique des maladies de l appareil digestif et de la nutrition, Hôpital Swynghedauw, Rue A Verhaeghe, F 59037 Lille Cedex, France
    Gut 55:1341-9. 2006
  3. pmc Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis
    S Fiorucci
    Department of Gastroenterology, University of Perugia, Perugia, Italy
    Br J Pharmacol 150:996-1002. 2007
  4. pmc Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis
    Jeffrey B Brown
    Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children s Memorial Hospital, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Gastroenterology 138:595-605, 605.e1-3. 2010
  5. ncbi Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations
    Runi A Foster
    Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Inflamm Bowel Dis 9:308-15. 2003
  6. ncbi Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies
    Fernando S Velayos
    Division of Gastroenterology and UCSF Center for Colitis and Crohn s Disease, University of California, San Francisco, California 94143, USA
    Am J Gastroenterol 100:1345-53. 2005
  7. doi 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study
    Charles N Bernstein
    University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Manitoba, Canada
    Am J Gastroenterol 106:731-6. 2011
  8. pmc Medications as a source of human exposure to phthalates
    Russ Hauser
    Department of Environmental Health, Occupational Health Program, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Environ Health Perspect 112:751-3. 2004
  9. doi Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study
    R Corinaldesi
    Department of Clinical Medicine and Center for Applied Biomedical Research, University of Bologna, Bologna, Italy
    Aliment Pharmacol Ther 30:245-52. 2009
  10. ncbi Systematic review: adherence issues in the treatment of ulcerative colitis
    S V Kane
    Section of Gastroenterology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    Aliment Pharmacol Ther 23:577-85. 2006

Detail Information

Publications257 found, 100 shown here

  1. ncbi Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
    Michael A Kamm
    Department of Gastroenterology, St Mark s Hospital, Watford Road, Harrow, United Kingdom
    Gastroenterology 132:66-75; quiz 432-3. 2007
    SPD476 (LIALDA in the US; MEZAVANT in the EU; otherwise known as MMX mesalamine; Shire Pharmaceuticals Inc., Wayne, PA, under license from Giuliani SpA, Milan, Italy) is a novel, once-daily, high-strength (1...
  2. pmc PPARgamma as a new therapeutic target in inflammatory bowel diseases
    L Dubuquoy
    INSERM U795 ex E114, Clinique des maladies de l appareil digestif et de la nutrition, Hôpital Swynghedauw, Rue A Verhaeghe, F 59037 Lille Cedex, France
    Gut 55:1341-9. 2006
    ..The aims of this review are to discuss the potential roles of PPARgamma in the physiopathology of IBD, as well as the emerging therapeutic strategies targeting this receptor...
  3. pmc Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis
    S Fiorucci
    Department of Gastroenterology, University of Perugia, Perugia, Italy
    Br J Pharmacol 150:996-1002. 2007
    b>Mesalamine is the first-line therapy for colitis, but it lacks potency and is only effective for mild-to-moderate forms of this disease...
  4. pmc Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis
    Jeffrey B Brown
    Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children s Memorial Hospital, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Gastroenterology 138:595-605, 605.e1-3. 2010
    b>Mesalamine is a mainstay therapeutic agent in chronic ulcerative colitis (CUC) in which condition it reverses crypt architectural changes and reduces colitis-associated cancer (CAC)...
  5. ncbi Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations
    Runi A Foster
    Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Inflamm Bowel Dis 9:308-15. 2003
    Lung injury related to mesalamine (5-aminosalicylic acid) has rarely been reported in patients with inflammatory bowel diseases...
  6. ncbi Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies
    Fernando S Velayos
    Division of Gastroenterology and UCSF Center for Colitis and Crohn s Disease, University of California, San Francisco, California 94143, USA
    Am J Gastroenterol 100:1345-53. 2005
    ..We performed a systematic review with metaanalysis of observational studies evaluating the association between 5-ASA use and colorectal cancer (CRC) or dysplasia among patients with ulcerative colitis...
  7. doi 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study
    Charles N Bernstein
    University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Manitoba, Canada
    Am J Gastroenterol 106:731-6. 2011
    ..We aimed to determine if use of 5-aminosalicylates (5-ASA) was associated with a reduced risk of colorectal cancer (CRC) in people with inflammatory bowel disease (IBD)...
  8. pmc Medications as a source of human exposure to phthalates
    Russ Hauser
    Department of Environmental Health, Occupational Health Program, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Environ Health Perspect 112:751-3. 2004
    ..we report on medications as a potential source of exposure to DBP in a man who took Asacol [active ingredient mesalamine (mesalazine)] for the treatment of ulcerative colitis...
  9. doi Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study
    R Corinaldesi
    Department of Clinical Medicine and Center for Applied Biomedical Research, University of Bologna, Bologna, Italy
    Aliment Pharmacol Ther 30:245-52. 2009
    ..Intestinal immune infiltration contributes to symptoms in patients with irritable bowel syndrome (IBS)...
  10. ncbi Systematic review: adherence issues in the treatment of ulcerative colitis
    S V Kane
    Section of Gastroenterology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    Aliment Pharmacol Ther 23:577-85. 2006
    ..It is a combination of understanding patient behaviour, recognizing signs of non-adherent behaviour and utilizing management strategies to change behaviour that will improve patient outcomes...
  11. doi Mesalamine protects against colorectal cancer in inflammatory bowel disease
    Jeffrey Tang
    Department of Internal Medicine, Division of Gastroenterology, Henry Ford Health System, Henry Ford Hospital, Detroit, MI 48202, USA
    Dig Dis Sci 55:1696-703. 2010
    ..Previous studies show this risk is strongly associated with dysplasia, extent of disease, duration of disease, and degree of inflammation, while chemoprevention of CRC has less support...
  12. doi Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine
    A Lyakhovich
    Department of Medicine, Medical University of Vienna, Austria
    Aliment Pharmacol Ther 31:202-9. 2010
    Mesalazine (mesalamine) (5-ASA) is considered an anti-inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis...
  13. pmc Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
    P W Lowry
    Division of Gastroenterology, Division of Clinical Pharmacology, Department of Pharmacology, and Section of Biostatistics, Mayo Clinic, Rochester, MN, USA
    Gut 49:656-64. 2001
    AIM: We evaluated the effect of coadministration of sulphasalazine, mesalamine, and balsalazide on the pharmacokinetics and pharmacodynamics of azathioprine and 6-mercaptopurine...
  14. doi Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 137:1934-43.e1-3. 2009
    It is not clear what induction dose of mesalamine is optimal for treating patients with mildly and moderately active ulcerative colitis (UC). This study was conducted to determine the efficacy and safety of mesalamine 4...
  15. ncbi Inflammatory bowel disease: clinical aspects and established and evolving therapies
    Daniel C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
    Lancet 369:1641-57. 2007
    ..Finally, we summarise the practical aspects of standard therapies including dosing, precautions, and side-effects...
  16. ncbi Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
    Matthew Rutter
    Department of Gastroenterology, University Hospital of North Tees, Stockton on Tees, Teesside, England
    Gastroenterology 126:451-9. 2004
    ..Patients with ulcerative colitis are at increased risk of colorectal cancer. It is widely believed that this is secondary to colonic inflammation. However, the severity of colonic inflammation has never been shown to be a risk factor...
  17. ncbi 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity
    Eleonora Distrutti
    Clinica di Gastroenterologia, Policlinico Monteluce, University of Perugia, Via Enrico Dal Pozzo, 06122 Perugia, Italy
    J Pharmacol Exp Ther 319:447-58. 2006
    ..In this study, we have investigated the role of a novel H(2)S-releasing derivative of mesalamine (5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester, ATB-429) in modulating nociception ..
  18. doi Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 138:1286-96, 1296.e1-3. 2010
    ..This study was conducted to determine the efficacy and safety of once-daily dosing of delayed-release mesalamine (Asacol 400-mg tablets) compared with twice-daily dosing for maintaining remission in UC patients.
  19. doi Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares
    P D R Higgins
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Aliment Pharmacol Ther 29:247-57. 2009
    ..Ulcerative colitis (UC) can be maintained in remission with 5-aminosalicylic acid (5-ASA) medications, but frequent non-adherence by patients who are feeling well has been associated with more frequent flares of colitis...
  20. ncbi Nonadherence in inflammatory bowel disease: results of factor analysis
    Petr Cerveny
    Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Prague, Czech Republic
    Inflamm Bowel Dis 13:1244-9. 2007
    ..The purpose of the study was to assess overall nonadherence to treatment among patients with Crohn's disease (CD) and ulcerative colitis (UC) in a single tertiary center...
  21. ncbi Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity
    Carina L Bos
    Laboratory of Experimental Oncology and Radiobiology, Department of Oncology, University of Amsterdam, The Netherlands
    Carcinogenesis 27:2371-82. 2006
    ..This study shows, using concentrations of mesalazine identical to concentrations seen in patients with inflammatory bowel disease, that mesalazine inhibits the Wnt/beta-catenin pathway via inhibition of PP2A...
  22. pmc Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma
    Christel Rousseaux
    Institut National de la Santé et de la Recherche Medicale 0114, Physiopathologie des Maladies Inflammatoires Intestinales, CHU 59037 Lille, France
    J Exp Med 201:1205-15. 2005
    ..Validation of these results was obtained with organ cultures of human colonic biopsies. These data identify PPAR-gamma as a target of 5-ASA underlying antiinflammatory effects in the colon...
  23. pmc Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs
    S G Nugent
    Department of Surgery, St George's Hospital Blackshaw Road, London, UK
    Gut 48:571-7. 2001
    ..This paper reviews methods for measuring gut pH, its changes in IBD, and how these may influence current and future therapies...
  24. doi 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis
    Margie L Clapper
    Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Inflamm Bowel Dis 14:1341-7. 2008
    ..The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia...
  25. ncbi Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells
    A Reinacher-Schick
    Department of Medicine, Ruhr University Bochum, Knappschaftskrankenhaus, Germany
    Carcinogenesis 24:443-51. 2003
    ..These findings may suggest a potential of mesalazine as a chemopreventive agent for colorectal cancer...
  26. doi Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis
    Michael A Kamm
    St Vincent s Hospital, Department of Medicine, University of Melbourne, Melbourne, Australia
    Inflamm Bowel Dis 15:1-8. 2009
    Many patients with ulcerative colitis (UC) respond to mesalamine therapy within 8 weeks. Those not achieving remission after 8 weeks are often treated with steroids or other immunosuppressive therapies...
  27. ncbi Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis
    Paul L McCormack
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 67:2635-42. 2007
    ..Two of 434 MMX mesalazine recipients experienced serious adverse events that were considered treatment related (pancreatitis caused by mesalazine sensitivity)...
  28. doi Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease
    Reikei Matsuda
    Department of Internal Medicine, Fujisawa Shounandai Hospital, Fujisawa, Kanagawa, Japan
    Inflamm Bowel Dis 15:328-34. 2009
    ..This study was to investigate the expressions of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 mRNAs in the colonic mucosa of patients with ulcerative colitis (UC) during active and quiescent UC...
  29. ncbi Mesalamine delivery systems: do they really make much difference?
    Altamash I Qureshi
    Department of Internal Medicine, Wayne State University, Detroit Medical Center, USA
    Adv Drug Deliv Rev 57:281-302. 2005
    ..aminosalicylates, which eliminate the sulfa-moiety, and attempt to target the topically active mesalamine to the inflamed bowel...
  30. doi Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pellets
    Ehab R Bendas
    Department of Pharmaceutics, College of Pharmacy, Oregon State University, Corvallis, OR, USA
    Drug Dev Ind Pharm 36:393-404. 2010
    ..The basic objective of this study was to develop a novel technique that aids in compaction of coated pellets into tablets and obtain a release pattern from compressed pellets resembling the same pattern before compression...
  31. doi Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis
    W Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Germany
    Aliment Pharmacol Ther 33:313-22. 2011
    Comparative data regarding different regimens of oral mesalazine (mesalamine) for maintaining remission in ulcerative colitis are limited.
  32. ncbi Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers
    W J Sandborn
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 19:1089-98. 2004
    Existing pharmacokinetic data are insufficient to determine whether a delayed-release formulation of mesalamine (Asacol) results in greater systemic exposure to 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid ..
  33. ncbi Current concept of pathophysiological understanding and natural course of ulcerative colitis
    Martin H Holtmann
    Department of Medicine, Johannes Gutenberg University, Langenbeckstrasse 1, 55131 Mainz, Germany
    Langenbecks Arch Surg 389:341-9. 2004
    ....
  34. doi Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?
    Peter Laszlo Lakatos
    1st Department of Medicine, Semmelweis University, Koranyi S 2A, H 1083 Budapest, Hungary
    Pharmacol Res 58:190-5. 2008
    ..In this systematic review, the authors summarize the available literature on the short- and medium-term efficacy and safety of the new once daily mesalazine formulations...
  35. doi Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study
    Fabrizio Bossa
    UU OO Gastroenterologia ed Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    Am J Gastroenterol 103:2509-16. 2008
    ..We planned a controlled study to investigate the efficacy and safety of dexamethasone 21-P (Dex 21-P) encapsulated into erythrocytes (DEE)...
  36. doi Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis
    Sunanda Kane
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 18:1026-33. 2012
    ..to assess clinical recurrence in patients with ulcerative colitis (UC) who received maintenance treatment with MMX Multi Matrix System (MMX) mesalamine. A secondary outcome was the relationship between long-term efficacy and adherence.
  37. ncbi Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse
    S R Ritland
    Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Arizona 85259, USA
    Clin Cancer Res 5:855-63. 1999
    ....
  38. doi Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cells
    S Parenti
    Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy
    Aliment Pharmacol Ther 31:108-19. 2010
    ..A recent observation has suggested that inhibition of beta-catenin signalling could induce these cellular effects...
  39. doi Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers
    Thai Hoa Joeres-Nguyen-Xuan
    Evangelisches Krankenhaus Kalk, Cologne, Germany
    Inflamm Bowel Dis 16:256-62. 2010
    b>Mesalamine and the probiotic E. coli Nissle 1917 (EcN) are both effective agents for the treatment of ulcerative colitis. A combined therapy may have more than additive efficacy. However, mesalamine may have antimicrobial effects on EcN.
  40. pmc One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis
    A Barney Hawthorne
    Department of Medicine, University Hospital of Wales, Cardiff, UK
    Inflamm Bowel Dis 18:1885-93. 2012
    ..We aimed to investigate whether OD Asacol was as effective as three times (TDS) daily dosing, and to evaluate the role of treatment adherence...
  41. doi The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway
    Johanna Munding
    Institute of Pathology, Ruhr University Bochum, D 44789, Germany
    Carcinogenesis 33:637-43. 2012
    ..Therefore, we suggest the use of 5-ASA as a promising drug for prevention of sporadic colorectal carcinoma...
  42. doi Small intestinal release mesalamine for the treatment of refractory celiac disease type I
    Shailaja Jamma
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Clin Gastroenterol 45:30-3. 2011
    The goal of this study is to evaluate the safety and efficacy of Small intestinal release mesalamine (SIRM) for symptom relief in refractory celiac disease (RCD).
  43. ncbi Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial
    B J Rembacken
    Centre for Digestive Diseases, The General Infirmary at Leeds, UK
    Lancet 354:635-9. 1999
    ..coli (Nissle 1917) was as effective as mesalazine in preventing relapse of ulcerative colitis. We also examined whether the addition of E. coli to standard medical therapy increased the chance of remission of active ulcerative colitis...
  44. ncbi Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease
    A Prakash
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 57:383-408. 1999
    ..4 g/day is effective in preventing postoperative recurrence of Crohn's disease. Oral delayed-release mesalazine is effective and well tolerated in sulfasalazine-intolerant patients with ulcerative colitis or Crohn's disease...
  45. pmc Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study
    Hiroaki Ito
    Digestive Disease Center of Excellence, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan
    Inflamm Bowel Dis 16:1567-74. 2010
    b>Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC.
  46. pmc Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents
    Melvin B Heyman
    Department of Pediatrics, University of California, San Francisco, California 94143 0136, USA
    Inflamm Bowel Dis 16:1931-9. 2010
    ..We conducted an open-label trial to evaluate the clinical efficacy of a mesalamine suppository (500 mg) to treat pediatric patients with mild to moderate ulcerative proctitis.
  47. ncbi Clinical pharmacokinetics of slow release mesalazine
    M De Vos
    Department of Gastroenterology, Ghent University Hospital, Belgium
    Clin Pharmacokinet 39:85-97. 2000
    ..Although preliminary data support an association between mucosal concentrations of mesalazine and its clinical activity, further studies are needed to correlate the effects of this drug with its pharmacokinetic parameters...
  48. doi Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, UK
    Am J Gastroenterol 106:2070-7; quiz 2078. 2011
    ..Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied this issue...
  49. ncbi Mesalamine for inflammatory bowel disease: recent reappraisals
    Giovanni C Actis
    Department of Gastro Hepatology, Ospedale Gradenigo, Torino, Italy
    Inflamm Allergy Drug Targets 7:1-5. 2008
    Derived from the historical molecule sulfasalazine, mesalamine has remained one of the mainstays for treatment of inflammatory bowel disease in the last 50 years...
  50. ncbi Mesalamine derivatives in the treatment of Crohn's disease
    Laura E Harrell
    Section of Gastroenterology and Nutrition, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 4076, Chicago, IL 60637, USA
    Gastroenterol Clin North Am 33:303-17, ix-x. 2004
    ..It remains to be determined whether certain high-risk groups of patients may benefit from higher doses of mesalamine induction or maintenance therapy. Mesalamine derivatives are also of benefit in the treatment of Crohn's disease...
  51. ncbi Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Rev Gastroenterol Disord 6:97-105. 2006
    Sulfasalazine, olsalazine, balsalazide, delayed-release mesalamine, controlled-release mesalamine, mesalamine pellets, and Multi-Matrix System mesalamine are effective first-line therapies for the treatment of mildly to moderately active ..
  52. ncbi Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis
    L P Piodi
    U O di Gastroenterologia, Servizio di Medicina Nucleare, Milan, Italy
    Scand J Gastroenterol 39:154-7. 2004
    ..Both the efficacy of long-term intermittent therapy with low-dose 5-ASA enemas in preventing UC relapses and its economic implications were evaluated...
  53. ncbi The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine
    Wolfgang Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Cologne, Germany
    Clin Gastroenterol Hepatol 1:36-43. 2003
    ..A new pellet preparation was designed combining slow and delayed release properties. Aims of the study were to find the optimal dose and to test efficacy and safety of a new 5-aminosalicylic acid formulation...
  54. ncbi Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial
    Stephen B Hanauer
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Gastroenterology 127:723-9. 2004
    ..The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical, endoscopic, and radiographic recurrence of Crohn's disease after ..
  55. ncbi Diagnosis and treatment of ulcerative proctitis
    Miguel D Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, Pennsylvania 15212, USA
    J Clin Gastroenterol 38:733-40. 2004
    ..This review highlights the pathogenesis, diagnosis, and treatment of ulcerative proctitis...
  56. ncbi Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 12:979-94. 2006
    ..The results of this review provided the content for the accompanying treatment guidelines, Clinical Guidelines for the Medical Management of Left-sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement...
  57. doi Ulcerative proctitis: a review of pharmacotherapy and management
    Peter Laszlo Lakatos
    Semmelweis University, First Department of Medicine, H1083 Budapest, Koranyi S 2A, Hungary
    Expert Opin Pharmacother 9:741-9. 2008
    ..Ulcerative proctitis (UP) is a common presentation of ulcerative colitis (UC)...
  58. ncbi A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis
    John I Mackowiak
    Center for Outcomes Research, Chapel Hill, North Carolina 27517, USA
    Manag Care Interface 19:39-46, 56. 2006
    ..results from clinical trials directly comparing oral balsalazide capsules and a specific formulation of oral mesalamine. Health care costs related to UC for an oral 5-ASA failure is greater than dollar 11,500 on average in the first ..
  59. pmc Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates
    Joel H Rubenstein
    The Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Am J Gastroenterol 104:2222-32. 2009
    ..Therefore, in patients prescribed 5-ASAs for maintenance of remission, annual surveillance might be overly burdensome and inefficient. We aimed to determine the ideal frequency of surveillance in patients with UC maintained on 5-ASAs...
  60. ncbi Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers
    Kenji Tokui
    Department of Pharmacy, Nagoya Daini Red Cross Hospital, Japan
    Biol Pharm Bull 25:264-7. 2002
    ..The present findings suggest that 5-ASA has favorable absorptive properties and can be expected to have systemic action after rectal administration of a 5-ASA enema...
  61. doi A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective
    Nic Brereton
    School of Health and Related Research ScHARR, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK
    J Med Econ 13:148-61. 2010
    ..To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective...
  62. ncbi Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing
    T B Vree
    Institute for Anaesthesiology, Academic Hospital Nijmegen Sint Radboud, Nijmegen, The Netherlands
    J Pharm Pharmacol 52:645-52. 2000
    ..8% metabolite with I and 15.5% with II. The renal clearance of the metabolite acetylmesalazine was independent of the observed defecation patterns (300 mL min(-1), P > 0.8), stool composition, and type of absorption...
  63. doi Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine
    Carmine Stolfi
    Department of Internal Medicine, University of Tor Vergata, Rome, Italy
    Gastroenterology 138:221-30. 2010
    b>Mesalamine has been reported to protect against inflammatory bowel disease-related colorectal cancer (CRC), but several drug-related issues have limited its use in chemopreventive programs...
  64. ncbi Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid
    Carmine Stolfi
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1 00133 Rome, Italy
    Biochem Pharmacol 75:668-76. 2008
    ..Taken together our data indicate that 5-ASA causes both a COX-2-dependent and -independent inhibition of CRC cell growth...
  65. ncbi Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis
    Antonio Tursi
    Digestive Endoscopy Unit, Lorenzo Bonomo Hospital, Andria BA, Italy
    Med Sci Monit 10:PI126-31. 2004
    ..25 g/day) plus 3 g/day VLS#3 (group A) with medium-dose balsalazide alone (group B) and with mesalazine (group C) in the treatment of mild-to-moderate active ulcerative colitis...
  66. doi Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis
    Antoine Cortot
    Gastroenterologie, Hopital Claude Huriez, Lille, France
    Am J Gastroenterol 103:3106-14. 2008
    To determine in a noninferiority study whether mesalamine foam is as effective as mesalamine liquid enema for inducing clinical remission in patients with active left-sided ulcerative colitis (UC).
  67. ncbi Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs
    William N Tindall
    Department of Family Medicine, Wright State University, Dayton, Ohio, USA
    J Manag Care Pharm 13:S2-12; quiz S13-4. 2007
    ..Continued disease progression and relapse of UC over time are associated with an increased risk of colorectal cancer (CRC)...
  68. ncbi Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers
    M Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, University of Vienna Medical School, Vienna, Austria
    Aliment Pharmacol Ther 17:1163-9. 2003
    ..Mesalazine (5-aminosalicylic acid)-containing formulations, designed to optimize drug delivery to the ileo-caecal region, represent a cornerstone in the treatment of inflammatory bowel diseases...
  69. doi Management of distal ulcerative colitis: frequently asked questions analysis
    S L James
    Department of Gastroenterology and Monash University Department of Medicine, Box Hill Hospital, Melbourne, Victoria, Australia
    Intern Med J 38:114-9. 2008
    ..The changes in guidelines have raised several management questions, many of which are addressed in this review...
  70. ncbi Prevention by intrarectal 5-aminosalicylic acid of N-methylnitrosourea-induced colon cancer in F344 rats
    Tomio Narisawa
    Akita University College of Allied Medical Sciences, Hondo, Japan
    Dis Colon Rectum 46:900-3. 2003
    ..The protective effect of 5-aminosalicylic acid against colon carcinogenesis was investigated...
  71. ncbi Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist
    Christine Linard
    Institut de Radioprotection et de Surete Nucleaire, Direction de la RadioProtection de l Homme, Laboratoire de Radiopathology, B P no 17, F 92262 Fontenay aux Roses Cedex, France
    J Pharmacol Exp Ther 324:911-20. 2008
    ..Collectively, these results indicate that PPAR agonists may be effective in the prevention of inflammatory processes and immune responses during and after pelvic radiotherapy...
  72. ncbi Aminosalicylic acid inhibits IkappaB kinase alpha phosphorylation of IkappaBalpha in mouse intestinal epithelial cells
    F Yan
    Department of Pediatrics, Division of Gastroenterology and Nutrition, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Biol Chem 274:36631-6. 1999
    ..These findings suggest a novel role for 5-ASA in the management of IBD by disrupting TNFalpha activation of NFkappaB...
  73. ncbi Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties
    A Tromm
    Department of Gastroenterology and Hepatology, BG Kliniken Bergmannsheil University Clinic, Bochum, Germany
    Hepatogastroenterology 46:3124-35. 1999
    ..However, the distinct therapeutic goal (acute phase treatment, maintenance therapy or post-operative prophylaxis), the involved areas of the gut and the specific release of the drug administered have to be considered...
  74. ncbi [5-aminosalicylates and colorectal cancer: preventive role in chronic inflammatory bowel disease?]
    Pierre Desreumaux
    Service des maladies de l appareil digestif et de la nutrition, Equipe INSERM Université 0114, CHU Lille
    Gastroenterol Clin Biol 28:509. 2004
  75. doi Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression
    Jaime Kaufman
    Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada
    Inflamm Bowel Dis 15:985-96. 2009
    ..In an effort to better understand the bacteriological effects of 5-ASA, we examined the role of this compound at the level of bacterial gene expression...
  76. ncbi Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study
    J R B Green
    Gastroenterology Unit, City General Hospital, Stoke on Trent, UK
    Aliment Pharmacol Ther 19:435-42. 2004
    ..The patient-centred approach is new to the management of ulcerative colitis. To date, it has only been shown to be successful in a short-term study...
  77. ncbi Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis
    Ronald Pruitt
    Vanderbilt University School of Medicine, Nashville Medical Research Institute, Nashville, Tennessee, USA
    Am J Gastroenterol 97:3078-86. 2002
    ..The study objective was to compare symptomatic remission rates with balsalazide and mesalamine while controlling for extent of disease and time since diagnosis in patients with active, mild-to-moderate ..
  78. doi Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine
    Xiaoming Deng
    Diagnostic and Molecular Medicine, Health Care Groups, VA Medical Center, Long Beach, California 90822, USA
    J Pharmacol Exp Ther 331:1071-8. 2009
    b>Mesalamine (5-aminosalicylate acid, 5-ASA) is an effective treatment for ulcerative colitis (UC). The mechanisms of its actions are not fully understood...
  79. pmc Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
    W Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Germany
    Gut 53:1617-23. 2004
    ..We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis...
  80. ncbi Effectiveness of mesalamine and propolis in experimental colitis
    Ahmet Aslan
    Department of General Surgery, Mustafa Kemal University, Antakya Hatay, Turkey
    Adv Ther 24:1085-97. 2007
    This study was conducted to investigate the effects of propolis and mesalamine on experimental colitis in rats. Distal colitis was induced in rats by intracolonic instillation of 2 mL of 4% acetic acid...
  81. ncbi Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis
    S B Hanauer
    Professor of Medicine and Clinical Pharmacology Chief, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, 5841 S Maryland Ave, MC 4076, Chicago, IL 60637, USA
    Aliment Pharmacol Ther 24:37-40. 2006
    ..6 g/day of mesalazine, although the absence of dose-related side effects allows continuation of the same inductive dose through maintenance treatment without dose-related toxicity...
  82. ncbi MMX mesalamine
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, Washington, USA
    Rev Gastroenterol Disord 6:146-52. 2006
    ..The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis...
  83. pmc 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint
    M Gloria Luciani
    Medical University of Vienna, Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Wahringer Gurtel 18, A 1090 Vienna, Austria
    Gastroenterology 132:221-35. 2007
    ..In this study, we hypothesized that 5-ASA restrains cell cycle progression by activating checkpoint pathways in colorectal cell lines, which would prevent tumor development and improve genomic stability...
  84. ncbi The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent
    Hillel D Cohen
    Department of Gastroenterology and Hepatology, Crohn s and Colitis Center of New Jersey, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Clin Gastroenterol 40:S150-4. 2006
    ..Several recent studies have evaluated the use of 5-ASA drugs (mesalamine) for the treatment of uncomplicated acute diverticulitis...
  85. ncbi Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine
    Sreedhar Subramanian
    Division of Gastroenterology, University School of Clinical Science, Liverpool, UK
    Inflamm Bowel Dis 14:162-75. 2008
    ..Mucosally adherent E. coli are found in inflammatory bowel disease (IBD) and colon cancer. They promote release of the proinflammatory cytokine interleukin-8 (IL-8). We explored mechanisms for this release and its inhibition by drugs...
  86. ncbi Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Am J Gastroenterol 100:2478-85. 2005
    Preliminary data have shown that delayed release oral mesalamine (Asacol) dosed at 4.8 g/day provided additional efficacy benefit compared to 1.6 g/day in patients with mildly to moderately active ulcerative colitis...
  87. ncbi Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism
    Daniel C Baumgart
    Department of Medicine, Division of Hepatology and Gastroenterology, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Germany
    Scand J Gastroenterol 40:958-64. 2005
    ..The aim of this study was to investigate whether 5-ASA also modulates intestinal epithelial wound repair in vitro...
  88. ncbi Mesalazine improves replication fidelity in cultured colorectal cells
    Christoph Gasche
    Department of Medicine 4, Division of Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria
    Cancer Res 65:3993-7. 2005
    ..This finding suggests that mesalazine improves replication fidelity, an effect that may be active in reducing mutations independent of its anti-inflammatory properties...
  89. ncbi A new oral delivery system for 5-ASA: preliminary clinical findings for MMx
    Cosimo Prantera
    Department of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Inflamm Bowel Dis 11:421-7. 2005
    ..This study had 2 objectives: (1) to evaluate the therapeutic response to MMx in patients with active left-sided disease and (2) to gain additional insights as to how the therapy would compare with topical 5-ASA...
  90. ncbi Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
    Gary R Lichtenstein
    Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 5:95-102. 2007
    SPD476 (MMX mesalamine), a novel, once-daily mesalamine formulation, uses MMX Multi Matrix System (MMX) technology to delay and extend delivery of active drug throughout the colon...
  91. ncbi 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease
    Jonathan P Terdiman
    University of California, San Francisco, San Francisco, California 94143 1623, USA
    Inflamm Bowel Dis 13:367-71. 2007
    ..The objective of this observational study was to determine if an association between 5-ASA therapy and CRC risk exists in IBD patients...
  92. ncbi Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats
    J L Wallace
    Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada
    Gastroenterology 117:557-66. 1999
    ..We evaluated whether a similar derivatization of mesalamine (5-aminosalicylic acid) would improve its anti-inflammatory activity.
  93. ncbi Possible mesalamine-induced pericarditis: case report and literature review
    Robert A Waite
    Department of Pharmacy Practice, Nesbitt School of Pharmacy, Wilkes University, Wilkes Barre, Pennsylvania 18766, USA
    Pharmacotherapy 22:391-4. 2002
    ..be considered in any patient complaining of chest pain and/or dyspnea who is taking a product that contains mesalamine or sulfasalazine...
  94. ncbi Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis
    P G Farup
    , , Norway
    Inflamm Bowel Dis 7:237-42. 2001
    ..The patients preferred the twice daily dosing...
  95. pmc Which 5-ASA?
    S P L Travis
    John Radcliffe Hospital, Oxford OX3 9DU, UK
    Gut 51:548-9. 2002
  96. ncbi Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis
    Sunanda Kane
    Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Am J Med 114:39-43. 2003
    We conducted a prospective study to determine the effects of nonadherence with mesalamine among patients with quiescent ulcerative colitis.
  97. ncbi Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid
    Charles N Bernstein
    Section of Gastroenterology, University of Manitoba Inflammatory Bowel Disease Clinical and Research Center, Winnipeg, Manitoba, Canada
    Inflamm Bowel Dis 8:356-61. 2002
    ..The scientific rationale for using these agents is sound but clinical data are lacking to fully support these approaches as chemoprevention in chronic colitis at present...
  98. ncbi Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
    S V Kane
    Department of Medicine, University of Chicago, Illinois, USA
    Am J Gastroenterol 96:2929-33. 2001
    ..METHODS: Outpatients with clinically quiescent ulcerative colitis for >6 months on maintenance mesalamine (Asacol, Procter and Gamble, Cincinnati, OH) were eligible...
  99. ncbi A pilot trial of Saccharomyces boulardii in ulcerative colitis
    Mario Guslandi
    Gastroenterology Unit, S Raffaele University Hosptial, Milan, Italy
    Eur J Gastroenterol Hepatol 15:697-8. 2003
    ..The aim of this study was to assess the efficacy of S. boulardii in ulcerative colitis patients...
  100. ncbi Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease
    M J Shale
    Department of Gastroenterology, Northern General Hospital, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
    Aliment Pharmacol Ther 18:191-8. 2003
    ..Non-compliance with maintenance mesalazine therapy may be a risk factor for relapse in inflammatory bowel disease, but the prevalence and determinants of non-compliance are unknown...
  101. ncbi Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouse
    D J MacGregor
    GI Research Lab, VA Medical Center, San Francisco, CA, USA
    Int J Oncol 17:173-9. 2000
    ..BSZ produces a dose-dependent chemopreventive effect on colon carcinogenesis. A possible mechanism is consistent with the inhibition of cellular proliferation and the induction of apoptosis...

Research Grants83

  1. Crossover Study on Human Exposure to Phthalates and Male Fertility
    Russ B Hauser; Fiscal Year: 2010
    ..S. population. The source of DBP exposure was Asacol (mesalamine, with enteric coating containing DBP) used to treat inflammatory bowel disease (IBD)...
  2. 5ASA REGULATION OF MNSOD IN INTESTINAL CELLS
    John Valentine; Fiscal Year: 2002
    ..The peak onset of IBD is between 15 and 25 years of age and the majority of patients with IBD are under age 40. Mesalamine (5-ASA) is the active ingredient in sulfasalazine and is one of the major therapies use to treat active disease ..
  3. Targeting Oxidative Stress in Chronic Beryllium Disease
    Brian Day; Fiscal Year: 2009
    ..The studies will mechanistically target these changes with a novel therapeutic approach using 5 aminosalicylic acid in CBD subjects. ..
  4. Targeting Oxidative Stress in Chronic Beryllium Disease
    Lisa A Maier; Fiscal Year: 2010
    ..The studies will mechanistically target these changes with a novel therapeutic approach using 5 aminosalicylic acid in CBD subjects. ..
  5. Behavioral Treatment of Nonadherence in Pediatric Inflammatory Bowel Disease
    KEVIN HOMMEL; Fiscal Year: 2007
    ..These evidence-based interventions should ultimately improve the effectiveness of health care and patient quality of life. ..
  6. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2004
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  7. Dioxins and Male Pubertal Growth and Development
    Russ Hauser; Fiscal Year: 2009
    ..The proposed study is unique since it will represent one of the first large longitudinal studies to explore the relationship of dioxins and PCBs with growth and development in pre-pubertal boys. ..
  8. Chemoprevention of Colitis-Associated Neoplasia by 5-ASA
    MARGIE CLAPPER; Fiscal Year: 2009
    ..Findings from the proposed mouse studies could lead to the use of 5-ASA for cancer prevention and significantly impact the establishment of future guidelines for the clinical management of patients with inflammatory bowel disease. ..
  9. Maternal Pesticide Exposure and Pregnancy Outcomes
    Russ Hauser; Fiscal Year: 2009
    ..Since the etiology of infertility and early pregnancy loss remains largely unexplained, the identification of potential environmental risk factors will have large public health significance. ..
  10. Trefoil Factors in GI Cancer Biology
    Steven Itzkowitz; Fiscal Year: 2009
    ..The results of these studies could provide insights into novel treatment strategies for gastrointestinal malignancies. ..
  11. Dioxins and Male Pubertal Growth and Development
    Russ B Hauser; Fiscal Year: 2010
    ..The proposed study is unique since it will represent one of the first large longitudinal studies to explore the relationship of dioxins and PCBs with growth and development in pre-pubertal boys. ..
  12. Adenosine in trauma and sepsis
    Gyorgy Hasko; Fiscal Year: 2010
    ....
  13. Chemoprevention of Colitis-Associated Neoplasia by 5-ASA
    MARGIE CLAPPER; Fiscal Year: 2009
    ..Findings from the proposed mouse studies could lead to the use of 5-ASA for cancer prevention and significantly impact the establishment of future guidelines for the clinical management of patients with inflammatory bowel disease. ..
  14. Preventing Neoplastic Progression in Ulcerative Colitis
    Thomas Ullman; Fiscal Year: 2007
    ..abstract_text> ..
  15. Genetic Studies in Crohn's Disease
    Jean Paul Achkar; Fiscal Year: 2007
    ..The PI will continue to recruit patients and controls for an IBD DMA bank that he recently started. This collection will then be used to pursue a case-control, haplotype-based analysis of Paneth cell candidate genes. ..
  16. PCBs, Phthalates and Male Reproductive Health
    Russ Hauser; Fiscal Year: 2007
    ..Based on our results, the optimal exposure assessment strategy for the proposed study is to collect three urine samples from all subjects on day 1, 2 and 31 of their study participation. ..
  17. Clinical Approaches to Ileal Pouch Dysfunction
    Bo Shen; Fiscal Year: 2005
    ..The AIMS of study are to 1) investigate visceral hypersensitivity using barostat examination of the pouch; 2) conduct a randomized, placebo-controlled clinical trial evaluating the use of amitriptyline in IPS. ..
  18. IKK Beta In Intestinal Inflammation
    Laurence Egan; Fiscal Year: 2005
    ..abstract_text> ..
  19. Analysis of the Chemopreventive Activity of FGN 1
    MARGIE CLAPPER; Fiscal Year: 2004
    ....
  20. TFF3 GENE EXPRESSION IN METASTATIC COLON CANCER
    Steven Itzkowitz; Fiscal Year: 2001
    ..The use of the TFF3 gene to drive expression of suicide genes offers a novel approach which should result in more targetted, safer gene therapy for metastatic colon cancer. ..
  21. Pathologic Markers of Genetic Damage and Disease in IBD
    Melvin Heyman; Fiscal Year: 2005
    ..abstract_text> ..
  22. Maternal Phthalate Exposure and Infertility, Fetal Loss
    Russ Hauser; Fiscal Year: 2005
    ..Since occupational and environmental exposure to phthalates is widespread, detecting even small adverse effects will have large public health significance. ..
  23. Test-Treat strategy to prevent ulcerative colitis relapse
    James Lewis; Fiscal Year: 2007
    ..The proposed study will test whether increasing mesalamine dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive ..
  24. Trefoil Factors in GI Cancer Biology
    Steven Itzkowitz; Fiscal Year: 2007
    ..The results of these studies could provide insights into novel treatment strategies for gastrointestinal malignancies. ..
  25. OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bo
    BRUCE SANDS; Fiscal Year: 2007
    ..We will follow these patients over time to determine the progression of their disease and to compare this to markers in the blood as a way of developing a system to predict the individual course of disease. ..
  26. Human Exposure to Bisphenol A, Phthalates and Fertility, Pregnancy Outcomes
    Russ Hauser; Fiscal Year: 2009
    ..The proposed study will investigate associations of phthalates and BPA with male and female fertility and pregnancy outcomes. ..
  27. Phthalates in Drugs and Male Genital Malformation
    Sonia Hernandez diaz; Fiscal Year: 2009
    ....
  28. The Epidemiology of Adipokines in Barrett's Esophagus
    Joel Rubenstein; Fiscal Year: 2007
    ..If so, measurement of these substances may be useful in a screening program. ..
  29. Comparative Effectiveness and Safety of Depression Treatments during Pregnancy
    Sonia Hernandez diaz; Fiscal Year: 2010
    ....
  30. Phthalates in Drugs and Male Genital Malformation
    Allen A Mitchell; Fiscal Year: 2010
    ....
  31. IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE
    BRUCE SANDS; Fiscal Year: 2004
    ..The principal investigator seeks to become an independent clinical investigator by completing the didactic and scientific portions of this proposal. ..
  32. Assessment of Infant Outcomes After in Utero Exposure to Antiretroviral Therapy
    Sonia Hernandez diaz; Fiscal Year: 2010
    ..We propose to evaluate the risk of congenital malformations and other adverse pregnancy outcomes following antenatal exposure to ART in a prospective cohort of pregnant women. ..
  33. IMURAN Dose Ranging Study in Crohn's Disease
    BRUCE SANDS; Fiscal Year: 2005
    ..Abstract Not Provided ..
  34. Chemoprevention of Colitis-Associated Neoplasia by 5-ASA
    Margie L Clapper; Fiscal Year: 2010
    ..Findings from the proposed mouse studies could lead to the use of 5-ASA for cancer prevention and significantly impact the establishment of future guidelines for the clinical management of patients with inflammatory bowel disease. ..